Mirtazapin Viatris (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Viatris, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral dosage form for oral use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapin Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapin Viatris is a NaSSA antidepressant used to address depressive disorders.

- Major depressive disorder: alleviates depressive symptoms and improves mood in adults. - Depressive episodes associated with anxiety: helps reduce anxiety‑related depressive features. - Treatment‑resistant depression (adjunct): may be added when first‑line agents are insufficient.

Mirtazapin Viatris may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Severe hypersensitivity reactions - Suicidal ideation or behavior - Hepatic dysfunction - Seizures (rare)

Before prescribing Mirtazapin Viatris, clinicians should consider several safety aspects.

- Monitor weight: patients may experience significant weight gain. - Assess sedation: caution when operating machinery or driving. - Evaluate hepatic function: use with care in liver impairment. - Review concomitant CNS depressants: risk of additive sedation. - Pregnancy and lactation: safety not established; weigh benefits against risks. - Store below 25°C: keep in the original pack, protect from moisture.

Mirtazapin Viatris can interact with several drug classes.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Other serotonergic agents: potential serotonin syndrome. - CNS depressants (e.g., benzodiazepines): additive sedation.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine): may increase mirtazapine levels. - Alcohol: enhances sedative effects. - Anticholinergic drugs: may increase anticholinergic burden.